TABLE 33Interventions, comparators, and baseline characteristics of participants in included studies: head-to-head comparisons

StudyArmDose (mg/day)Dosage detailsNAge, years (SD)Gender, n male (%)Race, n white (%)Weight, kg (SD)Education (years)Duration of dementia, months (SD)ADAS-cog, score (SD)MMSE, score (SD)
Bullock et al. 2005148Rivastigmine3–12Titrated from 3 mg/day for the first 4 weeks, up to a maximum of 12 mg/day in increments of 3 mg/day every 4 weeks49575.9 (6.60)154 (31.1)33.6 (22.2)15.1 (3.00)
Donepezil5–10Titrated from 5 mg/day for weeks 1–8 up to 10 mg/day in weeks 9–16

For patients who did not achieve the maximum dose during the titration period, investigators were asked to make at least one attempt during the maintenance period to increase the dose to the next highest dose level
49975.8 (6.80)157 (31.5)34.2 (26.5)15.1 (2.90)
Cumbo (2005)99Rivastigmine9aDosage/titration scheme not reported101b76.4 (rng 66–83)b43 (42.6)b5.00 (rng 3–12)b61.1 (rng 36–108)b16.6b
Galantamine16aDosage/titration scheme not reported
Donepezil10aDosage/titration scheme not reported
Ancoli-Israel et al. (2005)149Donepezil5–10Dose titrated from 5 mg once a day at night for the first 4 weeks up to 10 mg once a day at night for the remainder of study3277.8 (6.20)14 (43.8)26 (81.3)c19.4 (rng 13–24)
Galantamine8–16Dose titrated from 4 mg twice a day for the first 4 weeks up to 8 mg twice a day for remainder of study3176.5 (7.70)10 (32.3)25 (80.6)d19.3 (rng 11–24)
Nordberg et al. 2009147Donepezil5–10Starting dose 5 mg q.d.; after ≥ 4 weeks, if tolerated, up-titrated to 10 mg q.d.; no subsequent up-titrations2074.0 (8.00)9 (45.0)20 (100.0)65.2 (8.00)32.4 (19.2)20.0 (3.50)
Galantamine8–24Starting dose 4 mg b.i.d.; after ≥ 4 weeks, if tolerated, up-titrated to 8 mg b.i.d.; subsequent up-titrations could be made after ≥ 4 weeks at each dose, based upon the patient's well-being and tolerability to a maximum of 12 mg b.i.d.2173.7 (6.50)5 (23.8)21 (100.0)65.7 (11.5)39.6 (25.2)19.2 (3.10)
Rivastigmine3–12Starting dose 1.5 mg b.i.d.; after ≥ 4 weeks, if tolerated, up-titrated to 3 mg b.i.d.; subsequent up-titrations could be made after ≥ 4 weeks at each dose, based upon the patient's well-being and tolerability to a maximum of 6 mg b.i.d.2276.8 (8.90)5 (22.7)21 (95.5)65.1 (9.70)34.8 (25.2)18.8 (3.80)

b.i.d., twice a day; q.d., every day; rng, range.

a

Mean dose received during trial; allowable regimen not described.

b

Whole trial population; no data presented for individual arms.

c

26 (81.3%) at least high school.

d

22 (71.0%) at least high school.

From: 3, Assessment of clinical effectiveness

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.